Isofol Medical AB stock analysis
Isofol Medical AB (5IU) Stock Price & Analysis
5IU Stock Chart & Stats
- Day’s Range
- EUR 0.08 - EUR 0.08
- 52-Week Range
- EUR 0.04 - EUR 0.13
- Previous Close
- EUR 0.08
- Volume
- N/A
- Average Volume (3M)
- 2,000
- Market Cap
- EUR 30.52M
- Enterprise Value
- EUR 145.49M
- Total Cash (Recent Filing)
- EUR 114.83M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- Feb 12, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology Pipeline
A focused oncology candidate gives Isofol a defined development strategy rather than a broad, unfocused research portfolio. If clinical and regulatory objectives are achieved, arfolitixorin could support a scalable product opportunity within established chemotherapy treatment pathways.
Very Low Financial Leverage
Zero recent debt reduces fixed financing obligations and limits exposure to refinancing or interest-cost pressure. This gives management greater flexibility to allocate available resources toward clinical development and preserves balance-sheet resilience while the company remains pre-commercial.
Potential Partnering Pathway
The stated commercialization model provides more than one route to future monetization: Isofol could commercialize directly or pursue licensing and partnerships. Although conditional on development success, this creates strategic flexibility for funding, distribution, and revenue generation.
Bears Say
No Meaningful Commercial Revenue
The absence of meaningful revenue confirms that Isofol has not yet established a commercial earnings base. Until a product is approved and adopted, operating performance will remain tied to development progress rather than recurring customer demand or product sales.
Sustained Operating Cash Burn
Material operating cash consumption means Isofol cannot currently fund its activities from internally generated cash. Continued development therefore depends on existing reserves or additional financing, creating ongoing capital-raising pressure and potential constraints on operating plans.
Persistent Losses And Equity Erosion
Deep and recurring losses reduce the capital base and weaken earnings quality while the company remains pre-commercial. Continued negative profitability can limit financial flexibility, increase dependence on shareholders, and make progress toward self-sustaining operations more difficult.
Isofol Medical AB News
Isofol to Highlight Cancer Drug Candidate at BioStock Investor Meetings
Isofol Medical AB ( ($SE:ISOFOL) ) has issued an update. Isofol Medical AB, a Gothenburg-based clinical-stage biotech listed on Nasdaq Stockholm, is developing arfolitixorin, a proprietary next-generation folate treatment intended
5IU FAQ
What was Isofol Medical AB’s price range in the past 12 months?
What is Isofol Medical AB’s market cap?
When is Isofol Medical AB’s upcoming earnings report date?
How were Isofol Medical AB’s earnings last quarter?
Is Isofol Medical AB overvalued?
Does Isofol Medical AB pay dividends?
What is Isofol Medical AB’s EPS estimate?
How many shares outstanding does Isofol Medical AB have?
What happened to Isofol Medical AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Isofol Medical AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Petter Segelman Lindqvist
- Employees
- 6
- Website
- isofolmedical.com
- Address
- Biotech Center, Gothenburg, VG, 413 46, SE
Isofol Medical AB (5IU) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |










